• Explore /
  • Poster
  • / MLN0264, an investigational, first-in-class antibody-drug conjugate (ADC) targeting guanylyl cyclase C (GCC): Phase I, first-in-human study in patients (pts) with advanced gastrointestinal (GI) malignancies expressing GCC.

MLN0264, an investigational, first-in-class antibody-drug conjugate (ADC) targeting guanylyl cyclase C (GCC): Phase I, first-in-human study in patients (pts) with advanced gastrointestinal (GI) malignancies expressing GCC.

Abstract Poster

Authors

null

Khaldoun Almhanna

Moffitt Cancer Center, Tampa, FL

Khaldoun Almhanna , Wells A. Messersmith , Jordi Rodon Ahnert , Cristina Cruz , David P. Ryan , JungAh Jung , Adedigbo Fasanmade , Tim Wyant , Thea Kalebic

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

NCT01577758

Citation

J Clin Oncol 31, 2013 (suppl; abstr TPS3646)

DOI

10.1200/jco.2013.31.15_suppl.tps3646

Abstract #

TPS3646

Poster Bd #

14H

Abstract Disclosures

Similar Posters

First Author: Alexander I. Spira

Poster

2024 ASCO Genitourinary Cancers Symposium

Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC).

Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC).

First Author: Ding-Wei Ye

First Author: Gottfried E. Konecny

First Author: Soohyeon Lee